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ABSTRACT 
 
OBJECTIVE:  The objective of this selective EBM review is to determine if the addition of 
telaprevir reduces treatment time and is more effective than the presently available pegylated 
interferon α2a-ribavirin combination 48 week therapy. 
 
STUDY DESIGN:  Review of three English language primary studies published in 2011. 
 
DATA SOURCES:  Articles selected for review, are randomized, double blind, placebo 
controlled trials found in peer-reviewed journals using Cochrane, Medline and PubMed 
databases. 
 
OUTCOMES MEASURED:  Effectiveness of telaprevir was measured by determining the 
potentiality of reducing treatment outcome from 48 weeks to 24 weeks and the overall success 
rate of telaprevir as an add-on drug to the current therapy. 
 
RESULTS:  Jacobsen et al. (2011) found that 75% of patients using telaprevir as an add-on 
medication had SVR rates compared to 44% using placebo add-on. Sherman et al. (2011) found 
that a 24 week regimen of the currently available therapy with telaprevir added in the first 12 
weeks was non-inferior to the same regimen at 48 weeks duration.  No statistical differences 
were seen in variable dosing frequencies and intervals (P ≥0.787) and SVR was achieved in most 
patients with similar adverse reactions (Marcellin et al., 2011).   
 
The safety profile monitored adverse reactions seen including anemia, nausea, diarrhea and skin 
rashes.  Similar adverse reactions are seen with the current therapy; however incidence rate does 
increase with the triple therapy regimen.  All adverse reactions dissipated once medication was 
discontinued. 
 
CONCLUSIONS:  Data shows that telaprevir is an effective addition to the currently available 
therapy of peginterferon α-2a/ribavirin for chronic HCV genotype 1 patients.  The three studies 
selected for review suggest that a large proportion of patients would show promising results with 
addition of telaprevir for a 24 week treatment duration being used twice daily for the first 12 
weeks with similar adverse reactions and greater patient compliance than seen with the currently 
available therapy.   
 
KEY WORDS:  chronic HCV therapy, hepatitis C, current HCV treatment, telaprevir
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INTRODUCTION 
An estimated 200 million individuals worldwide are living with chronic hepatitis C virus 
(HCV) infection. In 2010, the annual incidence rate in the United States (U.S.) was estimated at 
17,000 individuals with 2.7 – 3.9 million living with chronic HCV.2 Caused by a single stranded 
RNA virus, the infection is the most common blood borne pathogen, the primary cause of liver 
dysfunction and decompensation, and the leading indication for liver transplantation in the U.S.9   
 HCV increases the risk for hepatic fibrosis, portal hypertension, compensated cirrhosis 
and hepatocellular carcinoma. The virus is also very promiscuous in that it will manifest 
throughout the body making its presence well known to healthcare providers.4 Patients often seek 
multi-specialty healthcare visits due to extra-hepatic manifestations affecting the skin, eyes, 
thyroid, immune system, small vessels, kidneys and salivary glands all of which are theorized to 
be immune mediated.4,5,6,10 Quantified annual healthcare visits are unknown due to variability in 
disease symptomatology, however it is known that costs correlate with disease severity. 
Healthcare visits and costs are lower for individuals unaware of viral infection and asymptomatic 
compared to individuals suffering from end stage liver disease.2 Annual costs per patient vary 
greatly and range from a mild chronic HCV condition ($145) to compensated cirrhosis ($585 - 
$1110) to hepatocellular carcinoma ($23,755 - $44,200) to liver transplantations ($201,110).3  
  Acute symptoms are seen in only 16% of patients,9 which is why 80% of those that 
become infected, progress to chronic carriers. Up to 90% of the chronic carriers advance to 
chronic liver disease. Of those patients, 20 – 30% progress to cirrhosis and a further 5 – 10% will 
develop hepatocellular carcinoma.1 Disease diagnosis is detection of anti-HCV or HCV RNA or 
both via serologic assay. Disease severity is determined via liver biopsy.9 
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Several genotypes of HCV exist. Genotype 1 is the most prevalent with patients yielding 
the poorest response to standard therapy.8 Current recommended therapy are weekly 
subcutaneous injections of pegylated interferon alpha-2a (PEG IFN-α2a) coupled with a daily 
weight based oral (PO) intake of 1000 – 1200 mg of ribavirin for 48 weeks. Response to therapy 
is clinically monitored by HCV RNA levels. Sustained virologic response (SVR), defined as a 
suppressed HCV RNA level 24 weeks after last treatment dose, is undetectable by serologic 
assay in 42 - 52% of patients using the currently available 48 week treatment.9 Side effects of 
treatment results in many patients being non-compliant with the 48 week therapy duration. These 
symptoms include but are not limited to fatigue, pruritus, anemia, nausea, headache, rash, 
insomnia, diarrhea and influenza-like illness.8 If conventional pharmacologic therapy is 
unsuccessful, liver transplantation may be required.9  
Research into new therapies is of great importance. Primarily due to the high prevalence 
of genotype 1 infection worldwide, of which, have comparatively poor response rates with the 
same treatment therapy than seen with HCV 2, 3, 4 & 6 genotypes. Secondly, the length of 
therapy duration complicated by significant physical side effects, result in poor patient 
compliance. Poor response rates and poor patient compliance lead to disease progression ending 
with high morbidity/mortality rates associated with high health care costs.8 One such new 
therapy is the addition of telaprevir, a serine protease inhibitor, to the currently available PEG 
IFN-α2a/ribavirin regimen which has been recently studied in treatment naïve patients.4,6,10   
OBJECTIVE 
The objective of this selective EBM review is to determine if the addition of telaprevir 
reduces treatment time and is more effective than the presently available PEG IFN-α2a/ribavirin 
combination 48-week therapy. 
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METHODS 
Three randomized controlled studies (RCT), two of which were double blind studies and 
one exploratory, open-label study, were chosen for this selective EBM review. The population of 
interest was chronic HCV genotype 1 patients. The intervention chosen was the addition of 
telaprevir to the current therapy of PEG IFN-α2a/ribavirin dual combination. Control and 
treatment groups were slightly variable between studies (Table 1). Inclusion criteria for studies 
were diagnosed chronic HCV genotype 1 patients, articles published after 2006 with outcomes 
that were evidenced based relevant to the patient. Exclusion criteria were liver disease derived 
from causes other than the HCV genotype 1 and hepatocellular carcinoma. Further study specific 
demographics and characteristics are listed Table 1. 
The author performed the article search in the Cochrane, Medline and PubMed databases 
using the keywords ‘chronic HCV therapy’, ‘hepatitis C’, ‘current HCV treatment’, and 
‘telaprevir’. All articles were published in peer-reviewed journals in the English language in 
2011. 
If stated, 95% confidence intervals were used with significance level of P < 0.05,4,6 non-
inferiority margin of -10.5% and an 80% power to rule out.10 Statistical tests used were a two-
sided, continuity-corrected chi-square test,4 non-inferiority comparison,10 and a logistical 
regression model.6 The number needed to treat (NNT) was calculated for each efficacy study. 
Number needed to harm (NNH), experimental event rate (EER), control event rate (CER), 
relative risk (RR) and absolute risk increase (ARI) were calculated for safety comparisons done 
in the Jacobson et al. (2011) and Sherman et al. (2011) studies. Marcellin et al. (2011) was not 
compared in the safety profile, as all adverse reactions were documented even if not specific to 
the medication involved or severity of reaction as the two formerly mentioned papers had done.  
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Table 1. Demographics and characteristics of reviewed EBM articles 
Study Type # Pts (n) Age Inclusion 
Criteria 
Exclusion 
Criteria 
W/D  Interventions 
Jacobson4 
(2011) 
RCT,  
double 
blind, 
placebo-
controlled 
total n = 
724 
 
PR:  
n = 361 
 
T12PR: 
n = 363 
18 – 
70 yo 
Chronic   
genotype 1 
HCV – 
determined 
by liver 
biopsy within 
12 mos of 
study 
 
Platelets ≥ 
90,000/mm3 
 
Absolute 
neutrophil 
count ≥ 
1500/mm3 
Decompensated 
liver disease 
 
Liver disease 
derived from 
other causes 
 
Hepatocellular 
carcinoma 
n = 57 Control (PR): 
placebo add on x 
12 wks, then 36 
current therapy 
 
Treatment 
(T12PR): 
telaprevir add on 
x 12 wks, then 12 
- 36 wks of 
current therapy 
Sherman10 
(2011) 
RCT, open 
label, double 
blind, phase 
3 non-
inferiority 
trial 
 
total n = 
322 
 
T12PR48: 
n = 160 
 
T12PR24: 
n = 162 
18 – 
70 yo 
Chronic HCV 
genotype 1 – 
determine via 
biopsy within 
6 mos of 
study 
 
Platelets ≥ 
90,000/mm3 
 
Absolute 
neutrophil 
count ≥ 
1500/mm3 
Hepatic 
decompensation 
 
Liver disease 
from other 
causes 
 
Active cancer 
within past 5 
years  
 
Co-infection of 
HBV or HIV 
n = 42 Control 
(T12PR48): 
telaprevir add on 
x 12 wks, then 
current therapy x 
36 wks. 
 
Treatment 
(T12PR24): 
telaprevir add on 
x 12 wks, then 
current therapy x 
12 wks  
Marcellin6 
(2011) 
RCT, 
exploratory, 
prospective, 
multicenter, 
open-label, 
phase 2 
clinical trial 
total n = 
80 
 
q8h: n = 
40 
 
q12h: n = 
40 
18 – 
65 yo 
Chronic HCV 
genotype 1 – 
determine via 
biopsy within 
18 mos of 
study 
 
Platelets ≥ 
100,000/mm3 
 
Absolute 
neutrophil 
count ≥ 
1500/mm3 
History of 
alcohol abuse 
 
Documented 
cirrhosis 
 
Evidence of 
other liver 
disease 
 
HIV co-infection 
 
PEG IFN or 
ribavirin med 
contraindication 
n = 6 Control (q8h): 
telaprevir 750 mg 
q8h x 12 wks + 
current therapy, 
then current 
therapy for 12 – 
36 wks 
 
Treatment 
(q12h): same as 
above except 
telaprevir 1125 
mg q12h  
Current therapy = PEG IFN-α2a/ribavirin 
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OUTCOMES MEASURED 
The author was interested in patient oriented outcomes that mattered (POEM) for chronic 
HCV genotype 1 individuals. POEMs selected were to determine if the addition of telaprevir was 
effective and/or non-inferior in reducing treatment duration from 48 to 24 weeks, as well as 
determining the effectiveness in therapy outcome when increasing dosage and reducing interval 
frequency. Since the majority of chronic cases of HCV are asymptomatic, to determine these 
outcomes, plasma HCV RNA levels were quantified using the COBAS TaqMan HCV assay, 
version 2.0 via blood samples taken during follow up study visits. Follow up visits varied 
between studies (min = 17, max = 19) and was dependent on patient response to treatment. 
Patients that achieved early undetectable HCV RNA levels were more likely to end treatment at 
24 weeks and therefore have less follow up study visits. All patients were included in a follow up 
post treatment study visit, which again varied between studies (min = 4 weeks, max = 48 weeks).  
HCV RNA levels were reported as either detectable (> 25 IU/mL) or undetectable (< 25 IU/mL).    
The safety profile for control and treatment groups were monitored by documenting 
adverse reactions to the medications seen in physical examination by investigators and described 
by patients during study visits. The severity of each adverse reaction was dependent on study 
protocols and criteria used.4,6,10 A side effect of ribavirin is anemia which is managed by dose 
reductions, if reductions in telaprevir were required in order to manage anemia in a patient, 
treatment was discontinued.9 In all studies, serious adverse events in patients were subject to 
treatment discontinuation in those patients as determined by investigators.4,6,10 
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RESULTS 
EFFICACY 
Jacobson et al. (2011) found statistical significance in patients with undetectable HCV 
RNA levels at the follow up study visit 24 weeks after the final treatment dose in the telaprevir 
(T12PR) group compared to the placebo (PR) group (75%, 44% respectively, P < 0.001). This 
study visit is also known as the primary end point (Table 2). All patients independent of 
treatment duration were tested at a 72 week follow up visit. Significance was seen in the T12PR 
group with undetectable HCV RNA levels compared to the control group (73%, 44% 
respectively, P < 0.001).4 Over half of the patients tested on follow up visit week 4, and 
collectively at week 4 and week 12, in the T12PR had undetectable HCV RNA levels. This 
compared to 9% and 8% of patients in the PR group at those respective study visits.4 Patients 
were again tested on the last day of treatment dosing. In the T12PR, this study visit was 
completed on either week 24 or week 48, depending on patient treatment duration. Of the total 
study sample size of n = 363, 314 had undetectable HCV RNA levels on week 24 or 48. All 
patients in the PR group received 48 weeks of treatment. The study sample size was n = 361 with 
a total of 229 patients having undetectable HCV RNA levels at week 48. Relapse, meaning 
detectable HCV RNA levels, among patients were tested 24 weeks after their last treatment dose 
in those that had undetectable HCV RNA levels at their last day of dosing. Of the 314 patients 
with undetectable HCV RNA levels on their last day of dosing, relapse occurred in 27 (9%) 
patients, compared to 64 out of 229 (28%) patients in the PR group.4 Results for Jacobson et al. 
(2011) are also referred to in Table 2. Based on data from the primary end point, four patients 
would need to be treated with telaprevir in order to prevent one additional patient being sampled 
for detectable HCV RNA levels. 
Nienaber, Telaprevir and Chronic HCV genotype 1- 7 
 
Table 2. Response during and after treatment period – n (%).4  
 
T12PR 
n = 363 
PR 
n = 361 
Undetectable HCV RNA during treatment period     
          At week 4 246 (68) 34 (9) 
          At weeks 4 and 12 212 (58) 29 (8) 
Undetectable HCV RNA 24 weeks after end of treatment:  
Primary end point 271 (75) 158 (44) 
Undetectable HCV RNA at 72 week follow up visit 265 (73) 158 (44) 
Relapse among patients with undetectable HCV RNA  
levels at end of treatment period 27/314 (9) 64/229 (28) 
 Number needed to treat = 4  
Sherman et al. (2011) was a non-inferiority trial testing a 24 week (T12PR24) vs. a 48 
week therapy regimen (T12PR48) with telaprevir being used in the first 12 weeks, (Table 3).  
The non-inferiority margin was pre-defined at -10.5%. At the primary end point study visit, the 
majority of patients obtained undetectable HCV RNA levels (T12PR24, 92%; T12PR48, 88%). 
The absolute difference between both groups was 4 percentage points (95% CI, -2 to 11). Both 
groups had similar and high rates of undetectable HCV RNA levels at week 4 and collectively at 
week 4 and week 12 (T12PR24, 100%; T12PR48, 99%).10 Low rates of relapse were also seen 
(T12PR24, 6%; T12PR48, 3%).10 Based on data from the primary end point, 23 patients need to 
be treated for 24 weeks to prevent one patient from having to do the full 48 week treatment. 
Table 3. Response during and after treatment period – n (%).10 
 
T12PR24 
n = 162 
T12PR48 
n = 160 
Undetectable HCV RNA during treatment period     
          At week 4 162 (100) 159 (99) 
          At weeks 4 and 12 162 (100) 159 (99) 
Undetectable HCV RNA 24 weeks after end of treatment:  
Primary end point 149 (92) 140 (88) 
Relapse among patients with undetectable HCV RNA  
levels at end of treatment period 9/159 (6) 4/154 (3) 
 Number needed to treat = 23 
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Marcellin et al. (2011) looked at different dosages of frequency interval in telaprevir 
usage. There was no significant difference in HCV RNA response between a 750 mg every 8 
hours (q8h) dose and an 1125 mg every 12 hours (q12h) dose at week 4, week 12 and end of 
treatment (P > 0.05, Table 4). Analysis also showed that patients had no significant difference in 
achieving SVR between the two treatment therapies (P ≥ 0.787). Patients that had undetectable 
HCV RNA levels between week 4 and week 20 were assigned to stop treatment at week 24 
(Table 4). Among the patients assigned to 24 weeks of treatment, 96.7 % (29/30) from the q8h 
group and 100% (29/29) from the q12h group achieved SVR.6 Amongst patients assigned to the 
48 week treatment duration, 83.3% (5/6) and 75% (3/4) from the q8h and q12h groups achieved 
SVR respectively.6 Based on primary end point data, 40 patients need to be treated at the 1125 
mg q12h before one additional adverse outcome would happen using the 750 mg q8h dosing. 
Table 4. Response during and after treatment period from pooled 24 and 48 week treatment 
durations – n (%).6 
 
q12h 
n = 40 
q8h 
n = 40 
Undetectable HCV RNA during treatment period     
          At week 4 33 (82.5) 32 (80) 
          At week 12 33 (82.5) 37 (92.5) 
Undetectable HCV RNA 24 weeks after end of treatment:  
Primary end point 33 (82.5) 34 (85) 
Undetectable HCV RNA at end of treatment 37 (92.5) 37(92.5) 
Undetectable HCV RNA at week 4 through week 20 29 (72.5) 30 (75) 
 Number needed to harm = 40 
SAFETY 
 In all three articles selected for review, 98 – 100% of patients in all groups independent 
of study experienced an adverse reaction. Most common adverse events were fatigue, pruritus, 
nausea, anemia and headache.4,6,10  Marcellin et al. (2011) recorded all events independent of 
Nienaber, Telaprevir and Chronic HCV genotype 1- 9 
 
severity or drug relatedness making safety comparisons with the following two studies not 
directly comparable. In Jacobson et al. (2011), 33 patients (9%) in the T12PR group had a 
serious adverse event compared to 24 patients (7%) in the PR group. Reactions were similar 
collectively between the two groups, most commonly seen being anemia (T12PR n = 8, PR n = 
4), psychiatric (T12PR n = 2, PR n = 3), musculoskeletal (T12PR n = 2, PR n = 3) and cardiac 
disorders (T12PR n=2, PR n = 2). The T12PR had two cases of rash which was not seen in the 
PR group, while the PR group had four cases of renal and urinary disorders, with zero cases 
notated in the T12PR group.4 In Sherman et al. (2011), serious adverse event incidences 
increased with duration of treatment (T12PR24, n = 4; T12PR48, n = 16). Most commonly seen 
were blood and lymphatic system disorders (T12PR24 n = 2, T12PR48 n = 5) and infections and 
infestations (T12PR24 n = 1, T12PR48 n = 5). Anemia was seen in one case in the T12PR24 
group, while pneumonia, metabolism and nutrition disorders, and dehydration were seen in the 
T12PR48 group.10 Treatment effects were calculated for all serious adverse reactions seen during 
the two studies that required patients to discontinue treatment (Table 5). For every 50 patients 
treated in the Jacobson et al. (2011) study, one additional patient would experience a serious 
adverse reaction. For every 12 patients treated in the Sherman et al. (2011) study, one fewer 
patient would have a serious adverse reaction. 
Table 5. Treatment effects for serious adverse reactions requiring treatment discontinuation. 
 
EER  CER  RR ARI NNT/NNH 
Jacobson et al. (2011) 0.09 0.07 1.29 0.02 50 
Sherman et al. (2011) 0.02 0.10 0.20 -0.08 -12 
 
DISCUSSION 
 Patients undergoing the current 48 week therapy of PEG IFN-α2a/ribavirin dual 
combination experience low response rates with higher relapse rates than compared to the 
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addition of telaprevir (Table 4).4,12 In addition to these less than desirable outcomes, patients still 
experienced adverse reactions independent of duration length or addition of telaprevir.4,12 
Presently, the potential to reduce treatment duration is limited to patients that can attain an early 
virologic response (EVR) seen at week 4, which is greater than a 2 log10 drop in HCV RNA level 
at baseline.4 Positive results have been shown with patients treated with response-guided therapy, 
in which patients that attain an EVR to the currently available treatment therapy benefit similarly 
in achieving SVR rates by stopping treatment at 24 weeks than at 48 weeks.7 In the three studies 
reviewed, EVR was achieved in 68 - 100% of patients using telaprevir as an add-on 
medication4,6,10 compared to 9% of patients observed in the placebo group in the Jacobson et al. 
(2011) study. This suggests that the majority of patients using telaprevir may benefit similarly by 
discontinuing treatment at 24 weeks than at 48 weeks.  Sherman et al. (2011) concluded that the 
same triple combination therapy for 24 weeks was non-inferior to 48 weeks (Table 3).   
Patient compliance improved in telaprevir groups that had reduced treatment durations.10 
Reducing frequency interval at which a drug must be taken on a daily basis is also important.6 
Currently, studies use telaprevir at a 750 mg dosage three times a day.4,6,8,10,11,12 Marcellin et al. 
(2011) showed similar adverse reactions (100% of patients in both groups) and response rates 
(Table 4) when increasing dosage to 1125 mg and decreasing frequency to twice daily.   
Safety profiles were consistent between the studies. Adverse reaction incidences increase 
with the use of telaprevir, with rash seen only with telaprevir use.4,6,9,12 Most commonly an 
eczematous type rash developing in the first 8 weeks4,6,10 and one case of Stevens-Johnson 
syndrome seen at 11 weeks after the final telaprevir dose.4 All rashes disappeared after telaprevir 
discontinuation.4,6,10 Overall, 99% of patients (n = 161) finished the 24 week treatment versus 
74% (n = 119) in the 48 week regimen in the Sherman et al. (2011) study, the majority of 
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patients discontinuing treatment were due to adverse reactions. This suggests that a decrease in 
treatment duration, even with an increased incidence of adverse reactions with telaprevir in the 
first 12 weeks, still improves patient compliance in the majority of patients undergoing therapy. 
All studies reviewed included treatment naïve patients with few that had advanced 
disease that tends to be more difficult to cure.4,6,10 Follow up studies should include a greater 
percentage of patients that are treatment naïve with advanced disease and patients with either no 
response or a relapse to original treatment. Another important consideration is cost effectiveness. 
Limited studies look at cost effectiveness using telaprevir as an add-on drug or comparatively to 
current therapy. A study recently published by Thorland et al. (2012) showed that telaprevir with 
the current dual combination therapy in treatment naïve patients and in response guided therapy 
would cost anywhere from £29,930 - 32,530 (US $38, 858 – 42, 234). This is comparable to a 
treatment naïve patient with advanced liver disease such as hepatocellular carcinoma, and much 
less than the cost of liver transplantation.3, 11 With the overall greater responses in EVR and SVR 
achieved with the addition of telaprevir, health care providers may opt to treat a patient 
diagnosed with chronic HCV genotype 1 initially with telaprevir as an add-on therapy rather than 
putting financial efforts into the current therapy which yields low response rates. 
CONCLUSIONS 
The three studies selected for review suggest that a large proportion of chronic HCV genotype 1 
patients would show promising results in the addition of telaprevir with a 24 week treatment 
duration using telaprevir twice daily for the first 12 weeks with similar adverse reactions but 
greater patient compliance than seen with the currently available therapy.  Further studies should 
look into patients with advanced liver disease, treatment experienced individuals, as well as the 
cost effectiveness between all drug regimens.    
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